Active ingredient
Olopatadine
114 finished FDA listings contain Olopatadine as their only active ingredient; 2 combination products also contain it.
FDA NDC Directory
- Ingredient names as written by FDA
- OLOPATADINE HYDROCHLORIDE
- Dosage forms
- Solution, Solution/ Drops, Spray, Spray, Metered
- Routes
- Nasal, Ophthalmic
- Manufacturers / labelers
- 53
- Strengths listed
- 1 mg/ml · 2 mg/ml · 5 mg/2.5ml · 665 ug/1 · 7 mg/ml
- Brand names in FDA listings
- Allergy Relief Eye Drops, Cvs Eye Allergy Itch Relief Once Daily, Cvs Eye Allergy Itch Relief Twice Daily, Equate Olopatadine Hydrochloride, Equate Olopatadine Hydrochloride Ophthalmic Solution, Eye Allergy Itch And Redness Relief, Eye Allergy Itch And Redness Relief Twice Daily Relief, Eye Allergy Itch Relief, Eye Allergy Itch Relief Once Daily Relief, Leader Olopatadine Hydrochloride, Leader Olopatadine Hydrochloride Ophthalmic Solution, Olopatadine Hcl, Olopatadine Hydrochloride, Olopatadine Hydrochloride Ophthalmic Solution, Olopatadine Hydrochloride Ophthalmic Solution Once Daily, Olopatadine Hydrochloride Ophthalmic Solution Twice Daily, Once Daily Relief, Pataday Once Daily Relief, Pataday Twice A Day Relief, Retaine Allergy
RxNorm (National Library of Medicine)
Ingredient concept RxCUI 135391
Drugs@FDA applications
Linked only where the FDA listing’s application number matches Drugs@FDA exactly. A listing in the NDC Directory does not by itself mean FDA approval.
| Application | Sponsor | Original approval | Listings |
|---|---|---|---|
| NDA 020688 | ALCON LABS INC | 1996-12-18 | 1 |
| NDA 021545 | ALCON LABS INC | 2004-12-22 | 1 |
| ANDA 091572 | APOTEX INC | 2014-10-08 | 1 |
| NDA 206276 | ALCON LABS INC | 2015-01-30 | 1 |
| ANDA 206306 | SOMERSET THERAPS LLC | 2015-12-07 | 2 |
| ANDA 203152 | USV | 2015-12-07 | 1 |
| ANDA 078350 | APOTEX | 2015-12-07 | 3 |
| ANDA 204812 | EUGIA PHARMA | 2015-12-18 | 15 |
| ANDA 202853 | PADAGIS ISRAEL | 2017-01-31 | 3 |
| ANDA 200810 | GLENMARK PHARMS | 2017-06-28 | 4 |
| ANDA 206046 | BAUSCH AND LOMB INC | 2017-07-26 | 6 |
| ANDA 090918 | APOTEX | 2017-12-05 | 1 |
| ANDA 206087 | BAUSCH AND LOMB INC | 2017-12-05 | 6 |
| ANDA 204392 | RISING | 2018-03-21 | 1 |
| ANDA 209919 | ALEMBIC | 2018-12-07 | 3 |
| ANDA 209995 | EUGIA PHARMA | 2019-04-04 | 17 |
| ANDA 209420 | ALEMBIC | 2019-04-29 | 4 |
| ANDA 209619 | GLAND | 2019-08-02 | 11 |
| ANDA 210901 | AMNEAL | 2020-01-28 | 1 |
| ANDA 209752 | GLAND | 2020-05-20 | 16 |
| ANDA 204620 | RISING | 2020-06-16 | 1 |
| ANDA 215006 | SOMERSET | 2024-12-18 | 1 |
| ANDA 219557 | GLENMARK PHARMS | 2025-02-28 | 5 |
| ANDA 213514 | GLAND | 2026-01-06 | 9 |
Official labeling on DailyMed
- OLOPATADINE HYDROCHLORIDE SOLUTION [YYBA CORP] · version 1 · 2026-09-02
- EYE ALLERGY ITCH RELIEF (OLOPATADINE HYDROCHLORIDE ) SOLUTION/ DROPS [TARGET CORPORATION ] · version 1 · 2026-08-17
- OLOPATADINE HYDROCHLORIDE SOLUTION/ DROPS [SOMERSET THERAPEUTICS, LLC] · version 8 · 2026-06-26
- EYE ALLERGY ITCH RELIEF SOLUTION/ DROPS [ALLEGIANT HEALTH] · version 2 · 2026-06-12
- OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION (OLOPATADINE HYDROCHLORIDE OPHTHALMIC) SOLUTION [GLAND PHARMA LIMITED] · version 2 · 2026-05-22
- OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION (OLOPATADINE HYDROCHLORIDE OPHTHALMIC) SOLUTION/ DROPS [GLAND PHARMA LIMITED] · version 2 · 2026-05-22
- OLOPATADINE SOLUTION/ DROPS [A-S MEDICATION SOLUTIONS] · version 1 · 2026-05-11
- OLOPATADINE HYDROCHLORIDE (OLOPATADINE HYDROCHLORIDE OPHTHALMIC) SOLUTION [GOLDEN STATE MEDICAL SUPPLY, INC.] · version 1 · 2026-05-04
- OLOPATADINE HYDROCHLORIDE SOLUTION [AMERISOURCEBERGEN DRUG CORP] · version 1 · 2026-05-01
- OLOPATADINE HYDROCHLORIDE (OLOPATADINE HYDROCHLORIDE OPHTHALMIC) SOLUTION [AMERISOURCEBERGEN DRUG CORP] · version 1 · 2026-05-01
- RETAINE ALLERGY (OLOPATADINE HYDROCHLORIDE) SOLUTION/ DROPS [OCUSOFT LLC] · version 3 · 2026-04-27
- OLOPATADINE HYDROCHLORIDE SOLUTION [SPORTPHARM LLC] · version 2 · 2026-04-27
Showing the 12 most recent of 108 labels.
Sources: FDA NDC Directory (2026-09-29), RxNorm, Drugs@FDA, DailyMed. Each source’s facts are shown separately as published.